A new legal case will test generic-drug makers' liability over product labeling. At issue is how quickly those companies need to match changes in labeling that are made by equivalent brand-name medicines.
via WSJ.com: US Business http://ift.tt/Ww1BQ4
via WSJ.com: US Business http://ift.tt/Ww1BQ4
Nessun commento:
Posta un commento